Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8190070 | 0.96 | KMT2A (0.60) | KMT2AMEN1TSHRALDH1A1KDM4E | |
| SCHEMBL13808520 | 0.84 | ALDH1A1 (0.55) | KMT2AMEN1TSHRALDH1A1KDM4E | |
| SCHEMBL12468980 | 0.83 | MEN1 (0.53) | KMT2AMEN1TSHRALDH1A1KDM4E | |
| SCHEMBL11892987 | 0.82 | KMT2A (0.55) | KMT2AMEN1TSHRALDH1A1KDM4E | |
| SCHEMBL13700884 | 0.82 | ALDH1A1 (0.56) | KMT2AMEN1ALDH1A1L3MBTL1LMNA | |
| SCHEMBL1302762 | 0.81 | SMN1; SMN2 (0.57) | KMT2AMEN1ALDH1A1KDM4ELMNA | |
| SCHEMBL6663904 | 0.81 | KMT2A (0.57) | KMT2AMEN1TSHRALDH1A1KDM4E | |
| SCHEMBL6905958 | 0.81 | KMT2A (0.57) | KMT2AMEN1TSHRALDH1A1KDM4E | |
| SCHEMBL8917273 | 0.80 | KDM4E (0.66) | KMT2AMEN1TSHRALDH1A1KDM4E | |
| SCHEMBL7512290 | 0.79 | KDM4E (0.55) | KMT2AMEN1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156624-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS INC (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008066641-A2 | METHODS FOR TREATING MITF ASSOCIATED DISEASES BY THE USE OF METHIONINE AMINOPEPTIDASE-2 INHIBITORS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-06-05 | — | — | WO | disclosed |
| US-7348307-B2 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2007124005-A2 | METHODS FOR TREATING BONE ASSOCIATED DISEASES BY THE USE OF METHIONINE AMINOPEPTIDASE-2 INHIBITORS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070161570-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070117758-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-7157420-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | KMT2A 446/4885MEN1 693/4885TSHR 1928/4885 |
| US-20070117758-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | KMT2A 4136/4885MEN1 700/4885TSHR 4341/4885 |
| US-20070161570-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, LNPEP | KMT2A 1477/4885MEN1 846/4885TSHR 4278/4885 |
| US-20090156624-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | KMT2A 446/4885MEN1 693/4885TSHR 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.